Two Milestone Studies in Liver Cancer Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38319792.
- Also identified by DOI 10.1056/EVIDe2200140.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunotherapy has changed the playing field for multiple cancers, and prime time for unresectable liver cancers may be here now. This issue of <i>NEJM Evidence</i> includes two trials describing novel immunotherapy options for patients with biliary tract cancer and hepatocellular carcinoma. Oh et al.<sup>1</sup> describe the results of the TOPAZ-1 trial, which resulted in improved overall survival for patients with biliary tract cancer in the frontline setting - the first real advance in more than a decade.<sup>2</sup> Abou-Alfa et al.<sup>3</sup> present results from the HIMALAYA study.